Ms. Linda Kisa reports

CRESCITA OBTAINS SHAREHOLDER APPROVAL TO BE ACQUIRED BY CLINACTIV HOLDINGS

At Crescita Therapeutics Inc.'s special meeting of shareholders held in person earlier today, shareholders voted overwhelmingly in favour of the special resolution approving the previously announced plan of arrangement involving the company, ClinActiv Holdings Inc. and its wholly owned subsidiary (the purchaser), pursuant to which the purchaser will acquire all of the issued and outstanding common shares of the company in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026. The target purchase price is 80 cents per share, subject to upward or downward adjustment based on the company's net working capital balance at the closing of the arrangement, subject to a minimum purchase price of 75 cents per share.

The arrangement resolution required approval of at least: (i) two-thirds of the votes cast by shareholders, present in person or represented by proxy at the meeting; and (ii) a simple majority (50 per cent plus one) of the votes cast by shareholders, present in person or represented by proxy at the meeting, after excluding for this purpose, votes attached to the shares held by persons described in items (a) through (d) of Section 8.1(2) of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions), which includes the shares held by Serge Verreault, Jose DaRocha and Linda Kisa.

The following is a summary of the votes cast at the meeting (including votes by proxy and in person at the meeting) by shareholders on the arrangement resolution.

The company's full report of voting results on the matter presented at the meeting, and the management information circular of the company dated April 10, 2026, that was mailed to shareholders in connection with the arrangement, can be found on SEDAR+ under the company's issuer profile.

The final order of the Ontario Superior Court of Justice (commercial list) approving the arrangement will be sought on May 20, 2026. Completion of the arrangement remains subject to receipt of the final order, and the company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of the date of this press release, the company anticipates that the arrangement will be completed in the second quarter of 2026. Upon closing of the arrangement, it is expected that the shares will be delisted from the Toronto Stock Exchange and that the company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.

About Crescita Therapeutics Inc.

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research and development and manufacturing capabilities. The company offers a portfolio of high-quality, science-based non-prescription skin care products and a commercial-stage prescription product, Pliaglis. It also owns multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin.

We seek Safe Harbor.